Baird Financial Group
ALNY icon

Baird Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Baird Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,379
Closed -$225K – 1769
2022
Q1 		$225K Buy
1,379
+185
+15% +$28.2K ﹤0.01% 1715
2021
Q4 		$202K Buy
1,194
+25
+2% +$4.65K ﹤0.01% 1817
2021
Q3 		$221K Buy
+1,169
New +$219K ﹤0.01% 1776

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Baird Financial Group's ALNY Position: Q2 2022 in Review

Baird Financial Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 1,379 shares — an estimated $225K sold.

Baird Financial Group first reported a position in ALNY in Q3 2021 and held it in 3 quarters. The position peaked at $225K in Q1 2022. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Baird Financial Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Baird Financial Group sold 1,379 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $225K.
  • Baird Financial Group first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Baird Financial Group's Alnylam Pharmaceuticals position peaked at $225K in Q1 2022.
  • 423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Baird Financial Group's 13F filing for Q2 2022, filed 8 Aug 2022.